Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: Diagnosis
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Diagnosis

1 evidence topic · 1 source

Mutational analysis before medical treatment

“It is strongly recommended to perform the mutational analysis in all GIST cases requiring medical treatment (II, A).” (opens the source at this quote in a new tab)